VERACYTE, INC. — Director's Dealing 2020

Sep 8, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERACYTE, INC. (VCYT)
CIK: 0001384101
Period of Report: 2020-09-04

Reporting Person: Kennedy Giulia C (Chief Scientific & Med Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-09-04	Common Stock	M	3542	$9.05	Acquired	83489	Direct
2020-09-04	Common Stock	M	2937	$5.98	Acquired	86426	Direct
2020-09-04	Common Stock	S	2536	$30.0505	Disposed	83890	Direct
2020-09-04	Common Stock	S	2350	$31.2082	Disposed	81540	Direct
2020-09-04	Common Stock	S	2141	$32.2356	Disposed	79399	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-09-04	Stock Option (right to buy)	$9.05	M	3542	Disposed	2027-03-02	Common Stock (3542)	Direct
2020-09-04	Stock Option (right to buy)	$5.98	M	2937	Disposed	2028-03-01	Common Stock (2937)	Direct

Footnotes

F1: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020.

F2: Represents weighted average sales price. Sale prices for the transactions range from $29.58 to $30.49. Detailed information regarding the number of shares sold at each separate price will be provided to the
SEC, the issuer or a shareholder upon request.

F3: Represents weighted average sales price. Sale prices for the transactions range from $30.69 to $31.68. Detailed information regarding the number of shares sold at each separate price will be provided to the
SEC, the issuer or a shareholder upon request.

F4: Represents weighted average sales price. Sale prices for the transactions range from $31.78 to $32.67. Detailed information regarding the number of shares sold at each separate price will be provided to the
SEC, the issuer or a shareholder upon request.

F5: The option becomes exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous
service thereafter.

F6: The option becomes exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous
service thereafter.